Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Fluorouracil
  • Hematologic Diseases
  • Prodrugs
  • Uridine

abstract

  • Treatment with oral PN401 beginning 8 hours after 5-FU administration is well tolerated and results in sustained plasma uridine concentrations above therapeutic-relevant levels. The recommended 5-FU dosage for phase II evaluations is 1,250 mg/m(2)/wk for 3 weeks every 4 weeks with the intensified PN401 dose schedule (schedule 2). At this dose, systemic exposure to 5-FU as measured by AUC was five-fold higher than that observed after administration of a conventional 5-FU bolus.

publication date

  • January 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10623707

Additional Document Info

start page

  • 167

end page

  • 77

volume

  • 18

number

  • 1